Clinical Research Directory
Browse clinical research sites, groups, and studies.
IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
Sponsor: University of Yaounde 1
Summary
This clinical trial will investigate the effect of standardized Irvingia gabonensis extract (IGOB131) on GLP-1 dynamics, DPP-4 activity, metabolic parameters, and inflammatory markers in adults with obesity. The study will compare IGOB131 to a placebo to find out if it exerts any significant metabolic benefits through GLP-1 and DPP-4 modulation, and the reduction of adiposity and systemic inflammation. Participants will: Take IGOB131 or a placebo every day for 16 weeks Visit the clinic once every 4 weeks for checkups and tests
Official title: Randomized, Double-Blind, Placebo-controlled Trial Of IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-12
Completion Date
2027-12
Last Updated
2026-10-20
Healthy Volunteers
No
Conditions
Interventions
IGOB131
IGOB-131 is an encapsulated, standardized botanical extract derived from Irvingia gabonensis.
Dextrin
Placebo capsules containing 400 mg of dextrin, looking identical to IGOB131 capsules